Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
June 02, 2021 07:00 ET
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
May 26, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics...
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
May 25, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
Progenity Announces Poster Presentations at Digestive Disease Week 2021
May 24, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted...
Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
May 21, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
May 12, 2021 07:29 ET
|
Progenity, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its...
Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD
May 11, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
May 06, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
May 05, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...